Nivolumab and ipilimumab +/-UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial).

Steven O'Day, Oliver Bechter, Paul Lorigan, Marta Nyakas

Research output: Contribution to journal › Meeting Abstract › peer-review

Research Beacons, Institutes and Platforms

This output contributes to the following UN Sustainable Development Goals (SDGs)

@article{758c6032244f4a6a9a42b8337d12b6e4,

title = "Nivolumab and ipilimumab +/-UV1 vaccine as 1st line treatment in patients with malignant melanoma (INITIUM-trial).",

author = "Steven O'Day and Oliver Bechter and Paul Lorigan and Marta Nyakas",

year = "2021",

month = jul,

language = "English",

volume = "81",

journal = "Cancer Research",

issn = "0008-5472",

publisher = "American Association for Cancer Research",

number = "13",

}